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Objective: Nigeria ranks fourth among the high tuberculosis (TB) burden countries. This 
study describes the prevalence of drug resistance and the genetic diversity of Mycobacterium 
tuberculosis in Abuja’s Federal Capital Territory. 
Materials and methods: Two hundred and seventy-eight consecutive sputum samples were 
collected from adults with presumptive TB during 2013–2014. DNA was extracted from Löwen-
stein–Jensen cultures and analyzed for the identification of nontuberculous mycobacteria species, 
detection of drug resistance with line probe assays, and high-throughput spacer oligonucleotide 
typing (spoligotyping) using microbead-based hybridization. 
Results: Two hundred and two cultures were positive for M. tuberculosis complex, 24 negative, 
38 contaminated, and 15 positive for nontuberculous mycobacteria. Five (2.5%) M. tuberculosis 
complex isolates were resistant to rifampicin (RIF) and isoniazid (multidrug resistant), nine 
(4.5%) to RIF alone, and 15 (7.4%) to isoniazid alone; two RIF-resistant isolates were also resis-
tant to fluoroquinolones and ethambutol, and one multidrug resistant isolate was also resistant 
to ethambutol. Among the 180 isolates with spoligotyping results, 164 (91.1%) were classified 
as lineage 4 (Euro-American), 13 (7.2%) as lineage 5 (West African 1), two (1.1%) as lineage 
2 (East Asia), and one (0.6%) as lineage 6 (West African 2). One hundred and fifty-six (86.7%) 
isolates were grouped in 17 clusters (2–108 isolates/cluster), of which 108 (60.0%) were grouped 
as L4.6.2/Cameroon (spoligotype international type 61).
Conclusion: The description of drug resistance prevalence and genetic diversity of M. tuber-
culosis in this study may be useful for improving TB control in Nigeria.
Keywords: tuberculosis, isoniazid, rifampicin, line probe assay, microbeads, spoligotyping
Introduction
Despite advances in its diagnosis and treatment, tuberculosis (TB) remains a global 
public health problem. In 2015, there were an estimated 10.4 million new TB cases 
and 1.4 million TB deaths worldwide, 480,000 new cases of multidrug-resistant TB 
(MDR-TB), and 100,000 cases of rifampicin (RIF)-resistant TB (RR-TB).1 Multidrug 
resistance is defined as resistance to both RIF and isoniazid (INH), and WHO recom-
mends that all patients with RR-TB should be treated with a second-line MDR-TB 
regimen. Nigeria has the fourth highest burden of TB in the world, with an estimated 
incidence of 322 per 100,000 people (2015). MDR-TB/RR-TB accounts for 4.3% of 
new cases and 25% of previously treated cases.1 However, these rates are likely to 
underestimate the problem, as a recent systematic review and meta-analysis reported 
that MDR-TB accounted for 6% of new and 32% of previously treated cases.2,3
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WHO recommends the use of line probe assays (LPA) to 
rapidly detect drug resistance to the most important first-line 
(RIF and INH), second-line (fluoroquinolones [FLQ]), and 
injectable drugs (kanamycin [KAN], amikacin [AMK], and 
capreomycin [CAP]).4 LPA are based on PCR amplification 
of rpoB (RIF), katG and the promoter of inhA (INH), gyrA 
and gyrB (FLQ), and rrs and the promoter of eis (KAN, 
AMK, CAP), and subsequent detection of mutations through 
hybridization to probes immobilized to a nitrocellulose 
membrane. Several molecular methods are available for the 
detection of first- and second-line drug resistance,5–11 and a 
commercially available LPA for this purpose is Autoimmun 
Diagnostika (AID) TB Resistance (AID Diagnostika, Stras-
sberg, Germany).12,13
Information on the Mycobacterium tuberculosis complex 
(MTBC) genotypes is useful for understanding the spread 
and phylogeographic specificity of predominant clones, as 
MTBC lineages have differences in virulence, transmissi-
bility, and capacity of acquiring drug-resistance conferring 
mutations.14,15 One of the most used genotyping methods 
is spacer oligonucleotide typing (spoligotyping), which is 
based on the detection of 43 spacers between the repeats in 
the clustered regularly interspaced short palindromic repeats 
(CRISPR) locus.16 Spoligotyping can be performed with a 
high-throughput microbead-based assay, which can also be 
used to detect molecular drug resistance to RIF and INH 
status with the Tuberculosis Rifampicin Isoniazid Typing 
(TB-RINT) technique.17–20
The aim of the present study was to describe the molecular 
drug resistance and genetic diversity of MTBC in Abuja, 
Nigeria. For this, cultured isolates were tested with three 
molecular methods to detect drug resistance and with 
microbead-based spoligotyping to obtain a snapshot of the 
MTBC genetic diversity.
Materials and methods
Study design
Adults with presumptive TB attending TB diagnostic clinics 
at district hospitals of Abuja Federal Capital Territory during 
2013 and 2014 were enrolled using consecutive sampling. 
Participants were asked to provide sputum samples on the 
spot, and samples were kept in a local refrigerator at 4°C 
until they were transported using a cold chain (4°C) to 
Zankli research laboratory in Abuja within 8 hours of collec-
tion. Specimens were cultured on duplicates using Löwen-
stein–Jensen medium. Duplicate cultures were then sent by 
courier at ambient temperature to the Hospital Universitari 
Germans Trias i Pujol (Badalona, Spain) for DNA extraction, 
 identification of nontuberculous mycobacteria (NTM), and 
detection of drug resistance with LPA. DNA samples were 
then sent in dry ice to the Institut de Biologie Intégrative de 
la Cellule (Orsay, France) for spoligotyping and detection of 
drug resistance with microbead-based hybridization.
DNA extraction
For DNA extraction, few colonies were resuspended in 250 
µL of molecular biology-grade water and were incubated at 
95°C for 30 minutes to inactivate the mycobacteria. DNA 
was extracted using Maxwell® 16 Viral Total Nucleic Acid 
Purification Kit (Promega Corporation, Fitchburg, WI, USA) 
following the manufacturer’s instructions. 
Identification of NTM species
Identification of NTM species was performed with the LPA 
Inno-Lipa Mycobacteria v2 assay (Fujirebio, Tokyo, Japan).21
Molecular detection of drug resistance
Molecular detection of drug resistance was performed with 
AID TB Resistance INH/RIF (AID Diagnostika), an LPA that 
targets wild-type regions and mutations in rpoB codons 516 
(GAC [D] to GTC [V] or TAC [Y]), 526 (CAC [H] to TAC 
[Y], GAC [D], or CGC [R]), and 531 (TCG [S] to TTG [L] 
or TGG [W]), associated with RIF resistance; and in katG 
codon 315 (S to T) and inhA positions −16 (A to G), −15 (C 
to T), and −8 (T to A or C), associated with INH resistance.12 
Four control probes (conjugate, amplification, Mycobacte-
rium genus, and MTBC controls) are present in each strip to 
verify the test procedures. All four control bands should be 
present to consider a result valid. AID TB Resistance assay 
was performed following the manufacturer’s instructions 
and hybridization and detection were performed with Auto-
Lipa (Fujirebio). The presence of all wild-type hybridization 
bands and absence of mutation bands indicate susceptibility 
to the drug considered. The absence of at least one wild-type 
hybridization band and/or the presence of any mutation band 
indicate resistance to the drug considered. The presence of 
all wild-type hybridization bands in combination with a 
mutation band in a target gene indicates heteroresistance, a 
combination of both susceptible and resistant M. tuberculosis.
In addition, molecular detection of drug resistance was 
performed with TB-RINT (Beamedex SAS, Orsay, France; 
www.beamedex.com), a 16-plex microbead-based hybridiza-
tion assay, as described previously.18,19 Briefly, rpoB, katG, and 
the promoter region of inhA were simultaneously amplified 
by PCR using dual-priming oligonucleotide primers, and the 
PCR product was hybridized to  oligonucleotide-precoupled 
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microbeads. Subsequently, detection was performed either 
with the flow cytometry-based Luminex 200 system 
(Luminex Corporation, Austin, TX, USA), XPONENT soft-
ware for LX100/LX200 (version 3.1.871.0), or BioPlex200 
(Bio-Rad Laboratories Inc, Hercules, CA, USA) running 
under Bio-Plex Manager 5.0. This assay targets wild-type 
regions and mutations in rpoB codons 516 (GAC [D] and 
GTC [V]), 526 (CAC [H], TAC [Y], and GAC [D]), and 531 
(TCG [S], TTG [L], and TGG [W]); katG codon 315 (ACG 
[S], ACC [T], and ACA [T]); and inhA positions −15 (C 
and T) and −8 (A). This assay may be used as a stand-alone 
assay or in association with spoligotyping, TB-SPOL, in one 
read only (TB-SPRINT, 59-Plex) on a Luminex 200 or on 
a FlexMap 3D, or in two reads (TB-SPOL and TB-RINT or 
TB-SPRINT-like) on a MagPix.
Isolates identified by LPA as resistant to RIF and/or INH 
underwent further molecular detection for FLQ, ethambutol 
(EMB), and injectable drugs (KAN, AMK, CAP) resistance 
using the LPA AID TB Resistance FQ/EMB, AID TB Resis-
tance AG, or pyrosequencing.10,12 AID TB Resistance FQ/
EMB targets wild-type regions and mutations in gyrA codons 
associated with FLQ resistance (codon 90 GCG [A] to GTG 
[V], codon 91 TCG [S] to CCG [P], and codon 94 GAC [D] 
to GCC [A], AAC [N], TAC [Y], and GGC [G]), and in embB 
codon 306 (ATG [M] to GTT [V], ATA [I], ATC [I], and ATT 
[I]) associated with EMB resistance. AID TB Resistance 
AG targets wild-type regions and mutations in rrs positions 
1401 (A to G), 1402 (C to T), and 1484 (G to C or T), which 
are associated with KAN/AMK/CAP resistance. Finally, 
pyrosequencing was performed as previously described.7,10 
Briefly, pyrosequencing targets gyrA codons 80 and 88–97, 
rrs positions 1401, 1402, and 1484, and embB codon 306. 
Pyrosequencing reaction and data analysis were performed 
as recommended by the PSQ96MA and SQA software manu-
facturer (Biotage AB, Uppsala, Sweden).
Spoligotyping
Spoligotyping was performed with the TB-SPOL kit (Bea-
medex SAS), a 43-plex microbead-based hybridization 
assay, as described previously.17 Briefly, the CRISPR region 
was amplified by PCR, and PCR products were hybridized 
to oligonucleotide-precoupled microbeads. Detection was 
performed as described for microbead-based detection of 
drug resistance. Numerical data were combined in a Micro-
soft Excel spreadsheet file and uploaded to BioNumerics 
version 6.1 software (Applied Maths, Kortrijk, Belgium). 
Spoligotyping patterns were compared with those in the 
International Spoligotyping Database (SITVITWEB) of 
the Pasteur Institute of Guadalupe (http://www.pasteur-
guadeloupe.fr:8081/SITVIT_ONLINE/), and spoligotype 
international types (SIT) and major phylogenetic clades were 
assigned.22 SIT numbers designate spoligotyping patterns 
shared by two or more patient isolates, respectively, whereas 
“orphan” designates patterns reported for a single isolate. 
When no SIT numbers were available in SITVITWEB, the 
designation “new-x” (lower cases) was given for patterns 
detected in single isolates and the designation “NEW-X” for 
new intra-study clusters. TB lineages were assigned using 
TBminer (https://info-demo.lirmm.fr/tbminer/).23 Lineages 
and sublineages were reported using the recent whole-
genome-based taxonomical nomenclature as suggested by 
Stucki et al24 and Coll et al.25
Ethics approval 
Ethical approval was obtained from the Research Ethics 
Committees of the Liverpool School of Tropical Medicine, 
the Nigerian National Ethics Committee, and Zankli Medical 
Centre. For this study, written informed consent to participate 
was obtained from all participants. In addition, patient data 
were anonymized, most researchers were blind to the patient 
data, and all data reported in the manuscript were obtained 
from cultured isolates.
Results
A total of 278 cultures were performed. Of these, 221 (79.5%) 
were positive, 24 (8.6%) negative, and 33 (11.9%) contami-
nated. One culture had two different colonies, and therefore, 
222 isolates were available for DNA extraction. Twenty of 
222 isolates were suspected to be NTM. NTM identification 
with Inno-Lipa Mycobacteria v2 identified Mycobacterium 
intracellulare (sequevars Min-A, -B, -C and -D) in four iso-
lates; Mycobacterium fortuitum– Mycobacterium peregrinum 
complex in three; Mycobacterium avium, Mycobacterium 
paratuberculosis, and Mycobacterium silvaticum in two; 
M. avium complex in one; Mycobacterium chelonae complex 
(group III, Mycobacterium abscessus) in one; Mycobacterium 
genus in four; and five were negative for Mycobacterium. 
Therefore, of 278 cultures, 202 (72.7%) had MTBC, 24 
(8.6%) were negative, 38 (13.7%) were contaminated, and 
15 (5.6%) had NTM (one was positive for both MTBC and 
NTM) (Table S1).
Molecular detection of drug resistance
AID TB Resistance INH/RIF results were obtained for the 
202 MTBC isolates, and 173 (85.6%) were sensitive to both 
INH and RIF, five (2.5%) were resistant to both INH and 
Infection and Drug Resistance  2018:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1620
Molina-Moya et al
RIF, nine (4.5%) resistant to RIF and sensitive to INH, and 
15 (7.4%) sensitive to RIF and resistant to INH (Table S1).
The microbead-based TB-RINT assay could be performed 
for 179 (89%) of the 202 MTBC isolates but no results were 
obtained for the 20 isolates suspected to be NTM (Table S1). 
Interpretable results for rpoB, katG, and inhA were obtained 
for 109 (60.9%), 112 (62.6%), and 112 (62.6%) isolates 
respectively. Regarding rpoB, 104 isolates were wild type, two 
harbored the H526D mutation, two the S531L mutation, and 
one the D516V mutation. Regarding katG, 108 isolates were 
wild-type and four harbored the S315T mutation. As for inhA, 
105 isolates were wild type and seven harbored the C-15T 
mutation. The results obtained with AID TB Resistance INH/
RIF and TB-RINT had 100% concordance (Table S1).
The 29 INH and/or RR isolates detected with AID TB 
Resistance were subjected to molecular analysis of resistance 
to FLQ, EMB, and KAN/AMK/CAP. Twenty-four were 
susceptible to FLQ, EMB, and KAN/AMK/CAP, two were 
resistant to FLQ and EMB, and one was resistant to EMB 
only. Results for EMB and KAN/AMK/CAP were missing 
for two isolates that were susceptible to the remaining drugs 
(Table 1). 
Spoligotyping
The microbead-based spoligotyping TB-SPOL assay was 
performed for 198 isolates, and an interpretable result was 
obtained for 180 (90.9%) (Table S1). Of these, 156 (86.7%) 
were grouped in 17 clusters, comprising between 2 and 108 
isolates. One hundred and eight (60.0%) were grouped as 
L4.6.2/Cameroon (SIT 61). Forty eight (26.7%) were grouped 
into 16 clusters, each comprising between two and six isolates. 
Twenty four isolates had unique patterns, which resulted in 41 
Table 1 Molecular drug resistance and spoligotyping results for the 29 isolates detected as resistant to RIF and/or INH with AID TB 
Resistance INH/RIF line probe assay
AID TB resistance TB-RINT Spoligotyping
RIF INH rpoB katG inhA FLQ EMB SLID gyrA embB 306 rrs rpoB katG 315 inhA Lineage/SIT
R R 531 mut mut wt S S S wt wt wt 531TTG 315C wt L4.6.2/Cameroon/SIT852
R R 531 mut mut wt S S S wt wt wt NP NP NP NP
R R 526 mut wt Ø wt S R S wt ATC wt NR NR NR L4.6.2/Cameroon/SIT852
R R 526 mut mut wt S S S wt wt wt NR NR NR L4.6.2/Cameroon/SIT838
R R 516 mut mut wt S S S wt wt wt 516GTC 315C wt L4.6.2/Cameroon/SIT61
R S 531 mut wt wt R/S R S A90A/ 
V, D94D/V
mut wt NR NR NR L5/afri/WA1/orphan
R S 531 mut wt wt R R S A90V ATC wt NP NP NP NP
R S 531 mut wt wt S S S wt wt wt 531TTG wt wt L4.6.2/Cameroon/SIT61
R S 531 mut wt wt S S S wt wt wt NR NR NR L4.6.2/Cameroon/SIT61
R S 526 mut wt wt S S S wt wt wt 526GAC wt wt L2/Beijing/SIT269
R S 526 mut wt wt S S S wt wt wt 526GAC wt wt L2/Beijing/SIT269
R S 526 mut wt wt S S S wt wt wt NR NR NR L4/T1/orphan
R S 526 mut wt wt S S S wt wt wt NP NP NP NP
R S 526 mut wt wt S S S wt wt wt NP NP NP NP
S R wt mut mut S S S wt wt wt wt 315C (−15)T L4.6.2/Cameroon/SIT852
S R wt mut wt S S S wt wt wt wt 315C wt L4.6.2/Cameroon/SIT61
S R wt mut wt S S S wt wt wt NR NR NR L4.6.2/Cameroon/SIT61
S R wt wt mut S S S wt wt wt wt wt (−15)T L4.6.2/Cameroon/SIT61
S R wt wt mut S S S wt wt wt wt wt (−15)T L4.6.2/Cameroon/SIT61
S R wt wt mut S S S wt wt wt wt wt (−15)T L4.6.2/Cameroon/SIT61
S R wt wt mut S S S wt wt wt wt wt (−15)T L4/T1/SIT53
S R wt wt mut S S S wt wt wt NR wt (−15)T L4/T1/SIT53
S R wt wt mut S S S wt wt wt NR NR NR L4.6.2/Cameroon/SIT61
S R wt wt mut S S S wt wt wt NR NR NR L4.6.2/Cameroon/SIT61
S R wt wt mut S NR S wt NR wt NP NP NP NP
S R wt wt mut S S NR wt wt NR wt wt (−15)T L4/new
S R/S wt wt wt/mut S S S wt wt wt NR NR NR L4.6.2/Cameroon/SIT61
S R wt wt wt Ø S S S wt wt wt NR NR NR L4/T2/SIT316
S R wt wt wt Ø S S S wt wt wt NR NR NR NR
Abbreviations: AID, Autoimmun Diagnostika; TB, tuberculosis; TB-RINT, tuberculosis rifampicin isoniazid typing, the microbead-based test for detecting drug resistance; 
RIF, rifampicin; INH, isoniazid; FLQ, fluoroquinolones; EMB, ethambutol; SLID, second-line injectable drugs (kanamycin, amikacin, capreomycin); SIT, spoligotyping international 
type; R, resistant; S, susceptible; R/S, heteroresistant; mut, mutation; wt, wild-type; wt Ø, absence of hybridization on the wild-type probe; NP, not performed; NR, no result 
obtained; afri, Mycobacterium africanum; WA1, West African 1; orphan, pattern described in SITVITWEB but without SIT number assigned.
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distinct spoligotyping patterns (Table 2). Of these, 26 were 
described and 15 were not described in the SITVITWEB. Four 
of the latter had been reported in an earlier study in Abuja in 
2012.26 The distribution of sublineages among the 180 isolates 
is shown in Table 2 and included L4.6.2/Cameroon (n=120, 
66.7%), L4.6.1/T2/Uganda (n=12, 6.7%), L4.1.1/X (n=4, 
2.2%), L4.1.2/Haarlem (n=2, 1.1%), L4.3.2/LAM3 (n=1, 
0.6%), L4/T1-not assigned (n=25, 10.6%), L5/Mycobacterium 
africanum WA1 (n=13, 7.2%), L2/Beijing (n=2, 1.1%), and 
L6/M. africanum WA2 (n=1, 0.6%). More broadly, of the 180 
isolates, 164 (91.1%) were classified as L4 (Euro-American), 
13 (7.2%) L5/M. africanum WA1, two (1.1%) L2 (East Asia), 
and one (0.6%) L6/M. africanum WA2 (Table 2).
Twenty three isolates with spoligotyping results were 
resistant to RIF and/or INH (Table 1). Four isolates with 
multidrug resistance were classified as L4.6.2/Cameroon: 
two as SIT852, one as SIT61, and one as SIT838. Six isolates 
were resistant to RIF and susceptible to INH. Of these, two 
were L2/Beijing/SIT269, two L4.6.2/Cameroon/SIT61, one 
L4/T1/orphan, and one L5/M. africanum WA1/orphan. Of 
13 isolates susceptible to RIF and resistant to INH, eight 
were classified as L4.6.2/Cameroon/SIT61, two as L4/T1/
SIT53, one as L4.6.2/Cameroon/SIT852, one as L4/T2/
UgandaI/SIT316, and one as L4/new (pattern not described 
in SITVITWEB). Resistance to RIF and/or INH was detected 
in 11/108 (10.2%) isolates classified as L4.6.2/Cameroon/
SIT61, 3/6 (50.0%) L4.6.2/Cameroon/SIT852, 1/5 (20.0%) 
L4/T2/UgandaI/SIT316, 1/4 (25.0%) L5/M. africanum WA1/
orphan, 2/2 (100%) L4/T1/SIT53, 2/2 (100%) L2/Beijing/
SIT269, 1/2 (50.0%) L4/T1/orphan (T1), 1/1 (100%) L4.6.2/
Cameroon/SIT838, and 1/1 (100%) L4/new (pattern not 
described in SITVITWEB) (Table 3). 
Discussion
We report a high proportion of isolates resistant to RIF, 
as detected with LPA and TB-RINT, and a large cluster 
Table 2 Spoligotyping results of the 180 samples with interpretable results
Lineage (n, %a) Sublineage (n, %a) SIT n (%a)
L4 (n=164, 91.1%) L4.6.2/Cameroon (n=120, 66.7%) 61 108 (60)
852 6 (3.3)
Orphan 3 (1.7)
403 2 (1.1)
838 1 (0.6)
L4/T2/UgandaI (n=12, 6.7%) 316 5 (2.8)
2088 5 (2.8)
848 2 (1.1)
L4/T1 (n=6, 3.3%) 53 2 (1.1)
Orphan 2 (1.1)
804 1 (0.6)
1580 1 (0.6)
L4.1.1/X (n=4, 2.2%) 200 4 (2.2)
L4.1.2/Haarlem (n=2, 1.1%) 49 1 (0.6)
1652 1 (0.6)
L4.3.2/LAM3 (n=1, 0.6%) 2428 1 (0.6)
L4/not assigned (n=19, 10.6%) NEW-3 3 (1.7)
1204 2 (1.1)
NEW-1 2 (1.1)
NEW-2 2 (1.1)
233 1 (0.6)
1872 1 (0.6)
Orphan 1 (0.6)
7 Different patterns not described in SITVITWEB 1 (0.6)
L5 (n=13, 62.8%) L5/afri/WA1 (n=13, 7.2%) Orphan 4 (2.2)
331 3 (1.7)
1592 1 (0.6)
5 Different patterns not described in SITVITWEB 1 (0.6)
L2 (n=2, 1.1%) L2/Beijing (n=2, 1.1%) 269 2 (1.1)
L6 (n=1, 0.6%) L6/afri/WA2 (n=1, 0.6%) 326 1 (0.6)
Note: aAmong the 180 samples.
Abbreviations: SIT, spoligotyping international type; LAM, Latin American-Mediterranean; afri, Mycobacterium africanum; WA, West African; Orphan, pattern described in 
SITVITWEB but without SIT number assigned.
Infection and Drug Resistance  2018:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1622
Molina-Moya et al
of M. tuberculosis isolates classified as L4.6.2/Cameroon/
SIT61, among patients with TB in Abuja, Nigeria.
In our study, according to genotypic drug susceptibility 
testing (DST), the rate of multidrug resistance was 2.5%, which 
is lower than the 11% reported in a previous study from our 
group, according to phenotypic DST.27 However, the limited 
sensitivity of genotypic DST for INH is noteworthy. In com-
parison, the rates of resistance in other states of Nigeria varied 
widely: 1.3% MDR in Kaduna (north Nigeria) according to 
genotypic DST,28 and 4.0% and 5.2% in two studies in Cross 
River, respectively,29,30 0% in Ibadan (south Nigeria),2 and 
32% in Lagos (south Nigeria)2 according to phenotypic DST. 
The differences in the prevalence of drug resistance between 
north and south Nigeria were highlighted in a recent systematic 
review, with the prevalence of MDR-TB among new patients 
being 3.0% in the north and 12.0% in the south (P<0.001).3 
The prevalence of MDR-TB among new patients in all of 
Nigeria was 6.0%, which is higher than the WHO estimate.1,3 
Interestingly, according to the DST method used – genotypic 
or phenotypic – this rate varied among new patients from 
4.0% to 7.0%, respectively, although the difference was not 
statistically significant.3
Genotypic and phenotypic DST present differences. The 
sensitivity of genotypic DST for detecting RIF resistance 
ranges from 95% to 98%, since the majority of mutations are 
located in the 81-bp core region of rpoB, which is targeted 
by most methods.31 However, a mutation located outside the 
81-bp core region, the Ile572Phe, accounted for up to one-
third of MDR-TB cases in Swaziland, resulting in many false 
negative results.32 Importantly, isolates harboring this muta-
tion are not consistently identified as resistant by phenotypic 
methods.33 It is important that the molecular method identifies 
the specific mutations detected, since different mutations 
confer different levels of resistance to one or more drugs 
in a family. For example, mutations H526D and H526Y in 
rpoB confer high-level resistance to all rifamycins, and their 
detection should exclude all rifamycins from treatment.31 In 
this study, codon 526 was mutated in seven isolates accord-
ing to LPA, but it was not possible to identify the specific 
mutation. However, mutation H526D could be identified with 
the TB-RINT microbead-based hybridization in two isolates. 
Regarding INH resistance, the sensitivity of genotypic 
DST is lower than phenotypic methods. The most common 
mutations targeted by the molecular methods, katG315 and 
inhA-15, detected 64% and 19% of the phenotypically resis-
tant cases globally.34 Thus, phenotypic resistance cannot be 
excluded for the isolates in our study that were classified as 
INH susceptible by LPA. It is especially important to detect 
INH resistance before starting the continuation phase of treat-
ment, since only RIF would be effective. In addition, the level 
of resistance is important, since low-level INH resistance 
(inhA promoter mutations) can be overcome with higher 
doses. In the present study, among the INH monoresistant 
isolates, three harbored the katG mutation and 12 harbored 
a mutation in the inhA promoter. It is of note that high-dose 
INH, even in cases with high-level resistance (katG muta-
tion), may still be effective.35
Mutations in gyrA were detected only in two isolates that 
were RR but INH-susceptible according to the LPA, and no 
mutations in rrs were detected; thus, no pre-extensively drug-
resistant isolates were identified in this study. The specificity 
of molecular methods for detecting FLQ and second-line 
injectable drug resistance is high; thus, after detection of a 
mutation in gyrA or rrs, these drugs should not be used for 
treatment.31 It is important to test for first- and second-line 
drug resistance to prescribe an effective treatment. This is 
especially critical after detecting RIF resistance with Xpert 
MTB/RIF – which is increasingly being adopted as the  initial 
Table 3 Distribution of the patterns of resistance to RIF and INH according to the spoligotyping patterna
Spoligotyping pattern RIFR/INHR
n (%)
RIFR/INHS
n (%)
RIFS/INHR
n (%)
RIFS/INHS
n (%)
NR 
n (%)
L4.6.2/Cameroon/SIT61 (n=108) 1 (0.9) 2 (1.9) 8 (7.4) 94 (87.0) 3 (2.8)
L4.6.2/Cameroon/SIT852 (n=6) 2 (33.3) – 1 (16.7) 3 (50.0) –
L4/T2/UgandaI/SIT316 (n=5) – – 1 (20.0) 4 (80.0) –
L5/afri/WA1 (n=4) – 1 (25.0) – 2 (50.0) 1 (25.0)
L4/T1/SIT53 (n=2) – – 2 (100) – –
L2/Beijing/SIT269 (n=2) – 2 (100) – – –
L4/T1/orphan (n=2) – 1 (50.0) – 1 (50.0) –
L4.6.2/Cameroon/SIT838 (n=1) 1 (100) – – – –
L4/new (n=1) – – 1 (100) – –
Note: aThis table includes only the spoligotyping patterns for which at least one isolate resistant to RIF and/or INH was detected. 
Abbreviations: RIF, rifampicin; INH, isoniazid; NR, no result obtained; afri, Mycobacterium africanum; SIT, spoligotyping international type; WA1, West African 1; orphan, 
pattern described in SITVITWEB but without SIT number assigned.
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diagnostic test for all individuals with presumptive TB in 
the Nigerian National Tuberculosis and Leprosy Control 
Programme.1 Despite these limitations, the rapid detection 
of drug resistance using molecular methods can be useful to 
exclude noneffective drugs and prevent the development of 
additional drug resistance.
The genetic diversity of M. tuberculosis isolates in Abuja 
described here updates that described by Lawson et al in 
2009–2010.26 The proportion of isolates classified was simi-
lar to those reported earlier: L4.6.2/Cameroon (66.7% and 
63.0%), L4.6.1/T2/UgandaI (6.7% and 11.7%), L4.1.1/X 
(2.2% and 0%), L4.1.2/Haarlem (1.1% and 5.2%), L4.3.2/
LAM3 (0.6% and 0.6%), L4/T1-not assigned (10.6% and 
7.1%), L5/M. africanum WA1 (7.2% and 8.4%), L2/Beijing 
(1.1% and 0.6%), L6/M. africanum WA2 (0.6% and 0.6%), 
and Mycobacterium bovis (0% and 2.6%). The clustering 
rate reached 87%, which is statistically similar to the 92% 
detected by spoligotyping by Lawson et al.26 However, 60% 
of the total isolates in the present study were classified as 
L4.6.2/Cameroon/SIT61. Due to this high clustering rate, 
further genotyping would be required to determine the real 
transmission rate of this clonal complex. In the previous 
study, isolates clustered with spoligotyping as L4.6.2/ 
Cameroon/SIT61 were partially resolved in six clusters 
by 24 variable number tandem repeat.26 L4.6.2/Cameroon/
SIT61, and the L4.6.2/Cameroon sublineage in general 
(spoligotyping signature lacking spacers 23–25 and 33–36) 
have been reported to be the main genotypic lineage in 
other Nigerian states (39.5% in Cross River36 and 66% in 
Ibadan)37 and in neighboring countries (66% in Cameroon,38 
33% in Chad,39 33% in Benin,40 and 30% in Burkina Faso).41 
The spread of this family could be associated with recent 
transmission of TB. In addition, L4.6.2/Cameroon/SIT61 
has been associated with young patients (25–34 years), 
suggesting recent transmission.36 Also, the prevalence of 
M. africanum is similar between the present study and the 
previous one by Lawson et al (7.8% and 9.1%).26 In Cross 
River, M. africanum represented 12% of TB cases and 
was classified as West African 1.36 Recent results from our 
team based on spoligotyping performed directly on sputum 
smears extracts show that M. africanum West African 1 is 
geographically constrained to a limited number of regions 
in South-East Nigeria and likely associated with specific 
populations.42 On the contrary, the prevalence of M. africa-
num is highly variable in different regions of Africa (3% in 
Cameroon38 and 20% in Ghana)43 with a decreasing trend 
in transmission over the last three decades.44 Research is 
needed to determine the mechanism(s) underlying the puta-
tive decreasing trend of M. africanum and the increasing 
selection and dissemination of the Cameroon sublineage in 
certain parts of Africa. 
Conclusion
We report a high proportion of isolates resistant to RIF, as 
detected with molecular methods, and a large cluster of 
L4.6.2/Cameroon/SIT61 isolates, indicating the spread of 
this sublineage in Nigeria. Future studies will be needed to 
describe changes on drug resistance patterns and genetic 
diversity of MTBC and to determine the evolution of TB 
transmission and drug resistance in this setting. These results 
may be useful to TB control programs to assess their impact 
on the control of drug resistance. The methods used here may 
be useful in other settings where phenotypic DST and more 
complex genotyping methods are not available.
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